Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4, Randomized, 52-Week Study To Evaluate Two Assessment Tools To Predict Treatment Success At 52 Weeks Based On A Treatment Decision At Week 12 In Subjects With Moderate To Severe Rheumatoid Arthritis Receiving Cimzia

NCT01255761 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT01255761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01255761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4, Randomized, 52-Week Study To Evaluate Two Assessment Tools To Predict Treatment Success At 52 Weeks Based On A Treatment Decision At Week 12 In Subjects With Moderate To Severe Rheumatoid Arthritis Receiving Cimzia
Lead sponsor
UCB Pharma
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2010
Completion date
December 31, 2012
Enrollment
736 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis